Tønnesen K H, Sager P, Gormsen J
Scand J Clin Lab Invest. 1978 Sep;38(5):431-5. doi: 10.3109/00365517809108447.
Forty-two patients, mean age 68 years, with severe leg ischaemia were randomly treated with placebo or by controlled defibrination with ancrod for 3 weeks. Plasma fibrinogen concentration was kept at about 20% of normal in the ancrod treated group. The two groups proved to be well matched regarding factors which could affect the degree of ischaemia. Objective measurements showed a significant rise in ankle and toe systolic blood pressure in the ancrod group lasting for 3 months. There was no rise in distal blood pressure in the control group. In the ancrod treated group the toe and ankle systolic pressures rose about 8 mmHg, but this was not accompanied by an improvement in the clinical course.
42名平均年龄为68岁的严重腿部缺血患者被随机分为两组,一组接受安慰剂治疗,另一组接受蝮蛇抗栓酶控制去纤维蛋白治疗,为期3周。在接受蝮蛇抗栓酶治疗的组中,血浆纤维蛋白原浓度维持在正常水平的约20%。两组在可能影响缺血程度的因素方面被证明具有良好的匹配性。客观测量结果显示,蝮蛇抗栓酶组的踝部和趾部收缩压显著升高,持续3个月。对照组的远端血压没有升高。在接受蝮蛇抗栓酶治疗的组中,趾部和踝部收缩压升高了约8 mmHg,但这并未伴随着临床病程的改善。